Drug pricing remains one of the most debated issues in American healthcare. While arguments rage on both sides, one fact is undeniable: a small group of medicines, mostly for rare genetic conditions, carry price tags that put them completely out of reach without insurance or manufacturer assistance. Many of these are part of the most expensive common prescription drugs sold in the US, and understanding why they cost so much requires looking at the diseases they treat and the complexity of producing them.
Gene Therapies Lead the Pack
Zolgensma remains the most expensive single treatment in the US, priced around $2.1 million. As a one-time gene therapy for spinal muscular atrophy, its cost is framed as an alternative to a decade of ongoing treatment. Luxturna, a gene therapy for inherited vision loss, follows a similar logic — a single injection priced at hundreds of thousands of dollars rather than years of recurring expense.
Zokinvy and the Cost of Rare Disease Treatment
Zokinvy precio searches are common among patients and caregivers trying to understand the true cost of this progeria treatment. Zokinvy can run over a million dollars annually depending on dosage, since pricing is based on body surface area. With no generic competitors and an extremely small patient population, manufacturers set prices high to recoup research investment — a pattern seen across nearly every drug on this list.
Brineura: Enzyme Replacement for Batten Disease
Brineura (cerliponase alfa) is the only enzyme replacement therapy approved for CLN2 disease, a form of Batten disease. People searching for brineura cost, brineura injection cost, or brineura injection price typically find that a single kit runs around $29,000, with annual treatment costing roughly $763,000. The cerliponase alfa cost reflects both the rarity of the condition and the lack of therapeutic alternatives — Brineura is delivered via intraventricular infusion every other week, requiring specialized administration that adds to the overall expense.
Ravicti for Urea Cycle Disorders
Patients managing urea cycle disorders often look up ravicti cost or revicti medicamento precio (a common spelling variation) when evaluating treatment options. Ravicti, an oral liquid medication, costs approximately $700,000 per year, with exact pricing varying by dosage and patient weight. Because it's one of the few approved options for this condition, cost competition is minimal.
Danyelza and Naxitamab Pricing
Danyelza, used for relapsed or refractory neuroblastoma, is built around the active ingredient naxitamab-gqgk. Families searching naxitamab precio are usually trying to estimate treatment costs for a child with this rare childhood cancer. A single vial costs over $22,000, and annual costs can range between $1.5 and $2 million depending on treatment duration, though most patients don't require year-long courses.
Lumizyme and Ongoing Enzyme Therapy
Lumizyme, used to treat Pompe disease, looks deceptively affordable per vial — around $905 — but patients typically need dozens of vials monthly based on body weight, pushing annual costs toward $600,000. This illustrates a recurring pattern: per-unit pricing on these drugs rarely reflects the true annual burden on patients and insurers.
What Drives These Prices
Across nearly every drug mentioned, a few factors repeat: small patient populations, lack of generic or biosimilar competition, expensive manufacturing processes (especially for biologics and gene therapies), and significant R&D costs that companies aim to recover quickly under patent protection. Unlike many countries, the US largely allows manufacturers to set prices without government intervention, which contributes to these extreme figures.
The Bottom Line
Manufacturer assistance programs, copay cards, and insurance negotiations often soften the blow for patients, but list prices alone tell a sobering story about the cost of treating rare diseases in America. As more specialized therapies enter the market, the conversation around affordability and access is unlikely to fade anytime soon.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.
Contact Information
Kanishk
